Elutia's Q1 Net Loss Widens 90% to $7.47M, Missing EPS Estimates
ELUT has more than doubled off its 52-week low of $0.5.
Summary
Elutia Inc. reported Q1 2026 revenue of $3.11 million, a net loss of $7.47 million, and diluted EPS of ($0.17). This net loss represents an 89.9% increase year-over-year and an EPS miss compared to analyst expectations of ($0.15). This follows an 8-K filing on May 14th which already indicated a "larger-than-expected net loss" for Q1 2026, but this 10-Q summary provides the specific financial figures. The significant widening of the net loss is a material negative for the company, despite a modest 5.5% revenue growth and positive operational updates like increased R&D spend on its drug-eluting biologic platform. Investors will monitor the progress of the NXT-41 and NXT-41x programs and the impact of the new direct sales channel on future margins.
At the time of this announcement, ELUT was trading at $1.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.5M. The 52-week trading range was $0.50 to $2.64. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.